Monday 23 November 2026 The business of healthcare in India, the UK and the Gulf
The Healthcare Daily
Get The Handover

MedTech and diagnostics

MHRA sets 6 November deadline for medical device annual registration fees

Updated MHRA guidance says device makers' accounts with unpaid 2026/27 annual fees will be suspended after 6 November. The charge is GBP 300 a year per Level 2 GMDN category.

Follow on Google News (opens in a new tab)
A long warehouse aisle between tall red racks stacked with cardboard boxes and pallets
Representative photograph: a warehouse aisle lined with stocked shelving. Getty Images for Unsplash+.

What you need to know

  • MHRA guidance updated on 16 October 2026 says outstanding 2026/27 annual registration fees for devices placed on the market must be paid by 6 November 2026, or accounts will be suspended.
  • The fee is GBP 300 a year per Level 2 GMDN category, or Level 1 where no Level 2 exists, and replaced a one-off registration fee from 1 April 2026.
  • In the 2025 consultation, 72 per cent of respondents did not support the charge; the government response proposed a move to full cost recovery in 2027/28.

The Medicines and Healthcare products Regulatory Agency (MHRA) has told medical device manufacturers that any outstanding annual registration fees for 2026/27 for devices placed on the market must be paid by 6 November 2026, and that accounts with unpaid annual fees after that date will be suspended. The deadline appears in the agency’s guidance on registering medical devices to place on the market, which was updated on 16 October 2026 with 2026/27 annual fees information in its fees section.

For the year from 1 April 2026 to 31 March 2027 the fee is GBP 300 a year for each Level 2 GMDN category, or Level 1 where no Level 2 category exists, according to the guidance. Manufacturers are charged according to how many categories their devices are registered under rather than per device, so several devices in one category attract a single annual charge. Categories are counted as held on 31 March, and registrations made during the year pay pro rata. The guidance says the fee will change annually. The MHRA recalculated the 2026/27 fees to exclude registrations for devices that are only put into service, for which MHRA registration is encouraged but not required.

The guidance does not say what a suspended account can and cannot do, and the MHRA has not published how many accounts have unpaid fees or how much it has collected.

How the annual charge came about

The annual fee replaced the previous one-off registration fee regime on 1 April 2026, when the MHRA also removed its renew registration function and some change fees, according to the guidance and its page history. An update on 26 June 2026 extended the annual fee payment deadline to 31 July 2026.

The charge follows a consultation on statutory fees. In its government response, published on 2 September 2025, the MHRA said 141 respondents (72 per cent) did not support the proposed fee on medical device post-market surveillance activities, 20 (10 per cent) supported it and 34 (18 per cent) did not know or had no opinion. The original proposal was GBP 210 a year for each GMDN category registered at the most detailed level, Level 5. The response moved the charge to Level 2 categories, with an estimated unit cost in the region of GBP 300 a year per category from 1 April 2026, and estimated that about 60 per cent of manufacturers would pay a single charge.

The stated rationale was that post-market surveillance of devices is mostly funded by a Department of Health and Social Care grant, which the response described as out of step with HM Treasury’s Managing Public Money guidance, and that post-market surveillance legislation in force since 16 June 2025 will increase workloads and demand. The response said the new fee would be part subsidised by government funding in 2026/27 and proposed a move to full cost recovery in 2027/28.

Who has to pay

The guidance says manufacturers are charged annually according to the number of Level 2 GMDN categories their devices are registered under, and the 6 November deadline applies to outstanding 2026/27 fees for devices placed on the market. Class I, IIa, IIb and III devices, together with in vitro diagnostic devices, custom-made devices and systems or procedure packs, must be registered with the MHRA before they are placed on the Great Britain market, the guidance says. Manufacturers based outside the UK must appoint a UK Responsible Person to handle registration; the guidance does not say whether the UK Responsible Person or the manufacturer pays the annual fee. Registrations and payments go through the Device Online Registration System (DORS). Adding devices under a new Level 2 category or changing the UK Responsible Person are chargeable changes; updating addresses and adding or removing products are free. Northern Ireland has separate rules: from 28 May 2026, medical devices other than custom-made devices must be registered on EUDAMED before they are placed on the Northern Ireland market.

Our reading

  • The Healthcare Daily’s reading: the 6 November date turns an annual bill into a compliance deadline. Because the guidance does not spell out the effect of suspension, manufacturers with outstanding fees, and UK Responsible Persons handling registrations for overseas manufacturers, cannot tell from it what access to their registrations they would keep after that date.
  • Charging by category favours focused portfolios. A manufacturer with many products in one Level 2 category pays once a year, while one whose range spans many categories pays for each, which matters most to broad-line suppliers and smaller firms with wide catalogues.
  • The 2026/27 fee is part subsidised, the government response proposed full cost recovery from 2027/28, and the guidance says the fee will change annually. Suppliers budgeting for the Great Britain market should treat GBP 300 as this year’s figure, not a fixed price.
  • The consultation drew majority opposition, and the MHRA has not published how many accounts are at risk of suspension. That number, if released, would show whether the deadline is likely to affect the range of devices registered for sale.

Questions readers ask

When is the MHRA medical device annual fee deadline?

Outstanding 2026/27 annual registration fees for devices placed on the market must be paid by 6 November 2026, according to MHRA guidance updated on 16 October 2026. Accounts with unpaid annual fees after that date will be suspended.

How much is the MHRA device registration annual fee?

For 1 April 2026 to 31 March 2027 it is GBP 300 a year for each Level 2 GMDN category, or Level 1 where no Level 2 exists. The charge is per category, not per device, and the guidance says it will change annually.

Do devices that are only put into service have to pay the MHRA annual fee?

The guidance says MHRA registration is encouraged but not required for devices that are only put into service. The MHRA recalculated the 2026/27 annual fees to exclude those registrations.

Sources

Announced plans, figures and dates are as stated in the sources below at the time of publication and can change. Conclusions drawn from them are our reading.

  1. MHRA (GOV.UK): Register medical devices to place on the market, guidance updated 16 October 2026
  2. MHRA consultation on statutory fees: proposals on ongoing cost recovery, government response (2 September 2025)

Topics

The Healthcare Daily. We report from primary sources and list them on every story.

Read our editorial policy

The Handover

In a hospital, the handover is when one shift tells the next what changed and what to watch. Ours does the same for the business of healthcare, every weekday morning once it launches.

One email each weekday after launch. Unsubscribe at any time.

Search The Healthcare Daily

Saved stories

Kept in this browser only. There is no account and nothing is sent to us.